-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $18

Benzinga·08/04/2026 13:20:31
Listen to the news
Wells Fargo analyst Benjamin Burnett maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight and lowers the price target from $20 to $18.